Society of Gynecologic Oncology 2021

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1 [Presentation Number 10224]

Comparative tolerability and dose modifications of poly(ADP-ribose) polymerase inhibitors in ovarian cancer: a retrospective cohort study of US healthcare claims data [Presentation Number 10487]

Real World Trends in Biomarker Testing in US Advanced Ovarian Cancer Patients [Presentation Number 11034]

ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status [Presentation Number 10226]

Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the Phase II LIGHT study [Presentation Number 10900]

Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary efficacy results from the Phase II LIGHT study [Presentation Number 10499]

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial [Presentation Number 10224]

RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high‐grade ovarian carcinoma [Presentation Number 10542]

Clinical Outcomes and Cost Associated with HRD Biomarker Guided First Line Maintenance Therapy in Advanced Ovarian Cancer [Presentation Number 11035]

DUO-E/GOG-3041/ENGOT-EN10: a randomized Phase III trial of first-line carboplatin and paclitaxel in combination with durvalumab, followed by maintenance durvalumab with or without olaparib, in patients with newly diagnosed advanced or recurrent endometrial cancer [Presentation Number 10518]

ADAGIO: a Phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma [Presentation Number 10640]